Skip to main content
SpringerLink
Log in

Can Clinical Guidelines Afford to Ignore Cost Effectiveness? An Ethical Perspective

  • Editorial
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cookson R. Justice and the NICE approach. J Med Ethics. 2015;41(1):99–102.

    Article  PubMed  Google Scholar 

  2. Harris J. QALYfying the value of life. J Med Ethics. 1987;13(3):117–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Rawles J, Rawles K. The QALY argument: a physician’s and a philosopher’s view. J Med Ethics. 1990;16(2):93–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Daniels N, Sabin JE. An ethical perspective. BMJ. 2008;337:a1850.

    Article  PubMed  Google Scholar 

  5. National Institute for Health and Care Excellence. NICE International Review 2014, London; 2014. http://www.nice.org.uk/media/default/About/what-we-do/NICE-International/NICE-International-Review-2014.pdf. Accessed 11 Feb 2016.

  6. Cagney H. UK cancer drugs fund to reassess 42 agents. Lancet Oncol. 2015;16(1):e8.

    Article  PubMed  Google Scholar 

  7. Baker H. Cancer drugs fund fails to collect patient outcomes. Lancet Oncol. 2015;6(15):e529.

    Article  Google Scholar 

  8. National Audit Office. Investigation into the cancer drugs fund. https://www.nao.org.uk/report/investigation-into-the-cancer-drugs-fund/. Accessed 11 Feb 2016.

  9. Montgomery v Lanarkshire HB [2015] UKSC 11.

  10. R (Burke) v General Medical Council [2005] EWCA Civ.1003, [50].

  11. Calabresi G, Bobbitt P. Tragic choices. New York: WW Norton & Company; 1978. p. 198.

    Google Scholar 

Download references

Acknowledgments

Peter Hall (clinician) and Kenneth Boyd (ethicist) each wrote draft outlines and specialist paragraphs from which Kenneth Boyd prepared a first draft: this was then edited by both authors and an agreed final draft submitted: both authors also approved the first and second revisions.

Author information

Authors and Affiliations

  1. Edinburgh, UK

    Kenneth Boyd & Peter Hall

Authors
  1. Kenneth Boyd
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Hall
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenneth Boyd.

Ethics declarations

Funding

This is an invited editorial. Neither Kenneth Boyd nor Peter Hall received any funding for this paper, which was written in their own time.

Conflicts of interest

Kenneth Boyd and Peter Hall have no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Boyd, K., Hall, P. Can Clinical Guidelines Afford to Ignore Cost Effectiveness? An Ethical Perspective. PharmacoEconomics 34, 529–531 (2016). https://doi.org/10.1007/s40273-016-0391-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40273-016-0391-2

Keywords

Search

Navigation